RJFSA
ALDX icon

Raymond James Financial Services Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-13,500
Closed -$71K – 2854
2019
Q3 		$71K Hold
13,500
– – ﹤0.01% 2673
2019
Q2 		$81K Hold
13,500
– – ﹤0.01% 2708
2019
Q1 		$122K Buy
13,500
+1,000
+8% +$8.5K ﹤0.01% 2617
2018
Q4 		$104K Buy
+12,500
New +$128K ﹤0.01% 2395

Other funds holding ALDX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

Raymond James Financial Services Advisors's ALDX Position: Q4 2019 in Review

Raymond James Financial Services Advisors sold out of Aldeyra Therapeutics (ALDX) in Q4 2019, closing a stake of 13,500 shares — an estimated $71K sold.

Raymond James Financial Services Advisors first reported a position in ALDX in Q4 2018 and held it in 4 quarters. The position peaked at $122K in Q1 2019. 77 funds tracked by Wall St. Rank hold ALDX as of Q4 2019.

  • Raymond James Financial Services Advisors reported no remaining Aldeyra Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 13,500 Aldeyra Therapeutics shares in Q4 2019, an estimated $71K.
  • Raymond James Financial Services Advisors first reported a position in Aldeyra Therapeutics in Q4 2018 and held it in 4 quarters.
  • Raymond James Financial Services Advisors's Aldeyra Therapeutics position peaked at $122K in Q1 2019.
  • 77 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.